U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H24ClN3O2
Molecular Weight 349.855
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PANCOPRIDE, (S)-

SMILES

NC1=C(Cl)C=C(C(=O)N[C@@H]2C[N@@]3CC[C@H]2CC3)C(OCC4CC4)=C1

InChI

InChIKey=DBQMQBCSKXTCIJ-MRXNPFEDSA-N
InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)/t16-/m1/s1

HIDE SMILES / InChI
Pancopride (LAS 30451) is a 5-hydroxytryptamine 3 receptor antagonist and was developed against cytotoxic drug-induced emesis. Pancopride was studied in clinical trials in patients treated with highly emetogenic chemotherapy. It was found a combination of Pancopride with dexamethasone was the most effective against chemotherapy-induced vomiting. However, information about the further development of this drug is not available.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
1992 Nov 10
LAS 30451: a novel 5-HT3 antagonist.
1993
Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers.
1995 Feb
Prevention of highly emetogenic chemotherapy-induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone.
1995 Nov-Dec
Lack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers.
1995 Oct

Sample Use Guides

Pancopride (PNC) 0.2 mg/kg. i.v. 30 min before chemotherapy
Route of Administration: Intravenous
Name Type Language
PANCOPRIDE, (S)-
Common Name English
BENZAMIDE, 4-AMINO-N-1-AZABICYCLO(2.2.2)OCT-3-YL-5-CHLORO-2-(CYCLOPROPYLMETHOXY)-, (S)-
Systematic Name English
Code System Code Type Description
PUBCHEM
72710794
Created by admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
PRIMARY
FDA UNII
2V4M6ABH0V
Created by admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
PRIMARY
CAS
137765-22-1
Created by admin on Sat Dec 16 11:02:01 GMT 2023 , Edited by admin on Sat Dec 16 11:02:01 GMT 2023
PRIMARY